The invention relates to a preparation in the form of a L. reuteri DAN080 culture, a partially inactivated L. reuteri DAN080 culture, a liquid supernatant of a L. reuteri DAN080 culture, a concentrated supernatant of a L. reuteri DAN080 culture and a dried or lyophilized supernatant of a L. reuteri DAN080 culture, as a therapeutic and prophylactic agent for the treatment and prevention of the development of gout (podagra) and/or increasing lysozyme activity in an organism of a vertebrate, other mammal or bird.Also a whole culture of L. reuteri DAN080, liquid supernatant, concentrated supernatant and dried or lyophilized supernatant obtained from a culture of L. reuteri DAN080, and from mixed bacterial cultures comprising L. reuteri DAN080, and liquid supernatants, concentrated supernatants and lyophilized supernatants obtained from cultures of prokaryotic and eukaryotic recombinants and whole cultures of prokaryotic and eukaryotic recombinants, in which and/or from which genes are utilized, which genes provide specific therapeutic and/or prophylactic activity in the treatment or prevention of development of gout (podagra), as well as proteins/oligopeptides/peptides of the molecular weight of approximately: 150 and/or 141 and/or 115 and/or 95 and/or 90 and/or 86 and/or 83 and/or 77 and/or 71 and/or 63 and/or 59 and/or 56 and/or 49 and/or 46 and/or 43 and/or 39 and/or 34 and/or 32 and/or 30 and/or 22 kD and lower purified/isolated from liquid/condensed/dried supernatant obtained from L. reuteri DAN080 and purified/isolated from whole cultures of L. reuteri DAN080 and from other mixed bacterial cultures comprising L. reuteri DAN080, and purified or isolated from cultures of prokaryotic and eukaryotic recombinants, in which and/or from which genes are utilized, which genes provide specific therapeutic and/or prophylactic activity in the treatment or prevention of development of gout (podagra), in accordance with the invention is a therapeutic and/or prophylactic agent f
